Announcing Investor Connect Plus: A LaunchBio x BIO Partnership
by Meredith Martindale
Accelerating Growth Through Connections
LaunchBio and the Biotechnology Innovation Organization (BIO) today announced the launch of Investor Connect Plus, an exclusive, BIO member-only investor access program designed for established, capital-ready life sciences companies seeking aligned institutional and strategic investment.
Investor Connect Plus is tailored for Late Seed through Series A–F private life sciences companies, as well as mature, private companies with commercial assets in global markets. Participating companies must demonstrate validated science, defined capital needs, and a clear use of proceeds. Each month, selected BIO member companies meet one-on-one with institutional and strategic investors who are actively deploying capital. These structured, curated meetings will be built around alignment in stage, sector, and investment thesis with the goal of moving beyond introductory exposure toward focused fundraising and growth discussions.
Investor Connect Plus reflects a strategic collaboration between LaunchBio and BIO to deliver a differentiated capital access pathway for mature life sciences companies. By combining LaunchBio’s curated investor engagement programming and national network with BIO’s global reach and member ecosystem, the partnership strengthens capital formation across distinct stages of company maturity to build better biotechs.
“Investor Connect Plus represents a natural evolution of our shared commitment to supporting innovative life sciences companies as they scale. Together, we are growing a structured environment where capital-ready companies can engage directly with aligned investors,” says Becky Beattie, CEO of LaunchBio.
“Investor Connect Plus strengthens BIO’s ability to connect small and emerging innovators with investors to help raise the capital they need to bring new therapies forward,” adds Brad Zakes, Senior Vice President of Emerging Companies and Economic Development at the Biotechnology Innovation Organization (BIO). “More than half of innovative new medicines originate in small to mid-size biotech companies. This partnership will help match the right innovators with the right investors to deliver more groundbreaking treatments to patients.”
BIO member companies may apply on a rolling basis for monthly consideration. Companies interested in participating must maintain an active BIO membership. Institutional and strategic investors interested in engaging with Investor Connect Plus may contact the program team directly.
Not a BIO member? BIO membership connects you and your team to the cost savings, partnerships, and policy solutions needed to drive biotech breakthroughs and advance your business.
